Vertex to buy VC-backed Semma for $950 mln
Vertex Pharmaceuticals Incorporated has agreed to acquire Cambridge, Massachusetts-based Semma Therapeutics, a biotech company focused on treating type 1 diabetes, for $950 million in cash. Semma's backers include Eight Roads Ventures, Cowen Healthcare Investments, MPM Capital, F-Prime Capital Partners, ARCH Venture Partners, Novartis, Medtronic, JDRF T1D Fund, ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital and SinoPharm Capital.
3 September 2019•5 mins read
